This makes it easier to handle the pretrial process under one judge
Recent developments: April 2026, The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, potentially limiting large-scale compounding activities
Based on the strength of the clinical data, we expect Wegovy to be added to formularies with utilization management restrictions for prior authorization to prevent off-label use, shorter initial approval periods (e.g., six months approved initially) to ensure efficacy, and quantity limits to reduce stockpiling and waste
Does tirzepatide cause fatigue in clients who use it
It was one of those oops nights, she says
The scope of research on this compound is currently limited to preclinical studies, with an absence of clinical data